Moderna (MRNA) Reports Q3 EPS Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results
November 6, 2019 7:00 AM ESTPositive interim results announced from Phase 1 CMV vaccine (mRNA-1647) study
Positive interim results announced from Phase 1 mRNA encoding chikungunya antibody (mRNA-1944) study
First participant dosed in Phase 1b age de-escalation study of hMPV+PIV3 vaccine (mRNA-1653)
Cash, cash equivalents and investments at the end of the quarter were $1.34 billion, and are expected to be approximately $1.20 billion at the end of 2019
Net cash used in operating activities and purchases of property and equipment is expected to total approximately $500 million in 2019, and between... More
